News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Suraj Samtani: Real-World Study of first Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma
Photo from Suraj Samtani/X
Oct 2, 2024, 15:14

Suraj Samtani: Real-World Study of first Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma

Suraj Samtani, Medical Oncologist at Harvard Medical School, shared a post on X, about recent paper published in Clinical Lung Cancer:

Efficacy of First-Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma: A Multicenter Real-World Study (ImmunoMeso LATAM).

Authors: Diego Enrico, Juan Elias Gomez, Danilo Aguirre, Natalia Soledad Tissera, Florencia Tsou, Carmen Pupareli, Delfina Peralta Tanco, Federico Waisberg, Andrés Rodríguez, Manglio Rizzo, Nicolás Minatta, Picon Rafael, Luis Basbus, Lorena Lupinacci, Diego Kaen, Mauro Ramos, Virginia Bluthgen, Nicolas Castagneris, María Pía Coppola, Alejandra Scocimarro, María Florencia Guerra, Aldo Perfetti, Patricio Levit, Marco Galvez-Nino, Luis Mas, Leonardo Rojas, Jairo Zuluaga, Matías Chacón, Luis Corrales, Suraj Samtani, Oscar Arrieta, Andrés Cardona, Jordi Remon, Claudio Martín.

Suraj Samtani

”Glad to share our latest article Real-World Study of 1st Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma.

A Great collaboration of many great colleagues led by Diego Enrico.”

Source: Suraj Samtani/X

Aldo Perfetti Alejandra Scocimarro Andres Cardona Andrés Rodríguez cancer Carmen Pupareli Claudio Martin Clinical Lung Cancer Danilo Aguirre Delfina Peralta Tanco Diego Enrico Diego Kaen Federico Waisberg Florencia Tsou Harvard Medical School ipilimumab Jairo Zuluaga Jordi Remon Juan Elias Gomez Leonardo Rojas Lorena Lupinacci Luis Basbus Luis Corrales Luis Mas Manglio Rizzo Marco Galvez-Nino María Florencia Guerra María Pía Coppola Matías Chacón Mauro Ramos Natalia Soledad Tissera Nicolas Castagneris Nicolás Minatta nivolumab OncoDaily Oncology Oscar Arrieta Patricio Levit Picon Rafael Suraj Samtani Virginia Bluthgen
Special Coverage
Insight
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer
Science
Dec 21, 2024, 07:05
Naseema Gangat: Practical prognostic tool for the current standard of care in older/unfit AML
Blog
Dec 21, 2024, 05:54
LCC in Spanish: LALCA 2024 Highlights
Blog
Dec 21, 2024, 05:50
The Opportunities Are Endless: CU Cancer Center leader Enrique Soto Pérez de Celis signs key international agreement
Insight
Dec 21, 2024, 05:42
Raffaella Casolino: How to integrate cancer into crisis?
Insight
Dec 21, 2024, 05:01
FDA Grants Dostarlimab Breakthrough Therapy Designation in dMMR/MSI-H Rectal Cancer
Blog
Dec 21, 2024, 05:01
Omolola Salako: A year ago, Pearl Oncology Specialist Hospital became a 24-hour, 10-bed cancer center
Science
Dec 21, 2024, 04:57
Alexandre Chan: Updates on repurposing riluzole as a treatment for cancer-related cognitive impairment
Blog
Dec 21, 2024, 04:55
Milan Mishkovikj: The Patient at the Center - Value-Based Healthcare in Oncology
Insight
Dec 21, 2024, 04:52
Do national cancer control plans address care and research for children and AYAs - SIOP
Insight
Dec 21, 2024, 04:36
A holistic global strategy for incorporating cancer care into crisis response initiatives - The Institute of Cancer and Crisis
Opinion
Dec 21, 2024, 03:42
The Dorcas Cancer Foundation's 12 Days of Thankful Giving